US Stock Insider Trading | Sera Prognostics disclosed 1 insider transaction on March 6

K-LinePoet · 2026-03-07T02:12:50+00:00

Sera Prognostics disclosed insider trading on March 6, 2026, with Director Lawrence Sandra AJ selling 1,560 shares at a price of $1.95 each, totaling $3,042.00. The company focuses on women's health diagnostics and is dedicated to developing biomarker tests to improve maternal and neonatal health.

K-LinePoet

2026-03-07 02:12:50

Abstract generation in progress

On March 6, 2026, Sera Prognostics (SERA) disclosed one insider transaction. Director Lawrence Sandra AJ sold 1,560 shares on that date.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 6, 2026	Director	Lawrence Sandra AJ	March 6, 2026	Sell	1,560	1.95	3,042.00
February 24, 2026	Executive	Harrison Robert Gardner	February 24, 2026	Sell	2,000	2.34	4,680.00
January 27, 2026	Executive	Harrison Robert Gardner	January 27, 2026	Sell	2,000	2.97	5,940.00
December 11, 2025	Executive	Jackson Benjamin	December 10, 2025	Sell	892	3.31	2,952.52
December 11, 2025	Executive	Aerts Austin	December 10, 2025	Sell	873	3.31	2,889.63
December 11, 2025	Executive	Boniface John J.	December 10, 2025	Sell	1,332	3.31	4,408.92
December 11, 2025	Director	Lindgardt Zhenya	December 10, 2025	Sell	4,155	3.31	13,800.00
December 11, 2025	Executive	Kearney Paul	December 10, 2025	Sell	1,213	3.31	4,015.03
December 11, 2025	Executive	Harrison Robert Gardner	December 10, 2025	Sell	616	3.31	2,038.96
December 10, 2025	Director	Lindgardt Zhenya	December 9, 2025	Sell	28,200	3.04	85,800.00

[Company Information]

Sera Prognostics, Inc. was incorporated on January 17, 2008, under Delaware law. The company is a women’s health diagnostics company that leverages its proprietary proteomics and bioinformatics platform to discover, develop, and commercialize biologically and clinically meaningful biomarker tests. The company’s initial focus is on improving pregnancy outcomes. Its vision is to provide key and actionable information to pregnant women, physicians, and healthcare payers to significantly improve maternal and neonatal health and substantially reduce healthcare costs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes